Treatment of drooling in children with cerebral palsy using ultrasound guided intraglandular injections of botulinum toxin A

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The aim of this study was to determine whether botulinum toxin A (BTX-A), injected into both parotid and submandibular salivary glands of children with cerebral palsy and sialorrhea, could decrease their drooling and improve their quality of life. Twenty-one children aged 4 to 12 years (mean age 8.4 years) received 60-80 units BTX-A (mean dose 3.6 U/kg) under sedation using ultrasound guidance. Response was assessed by several methods (drool frequency and severity score, drool quotient, number of bib changes per day and a visual analogue score) at baseline, 2, 8 and 16 weeks post-injection. A questionnaire related to quality of life and caregiver satisfaction was administered at baseline and week 8. Adverse events were recorded at each visit. Drool frequency and severity scores were significantly reduced at weeks 2, 8 and 16 compared to baseline (P < 0.001). Significant reductions were also seen for the visual analogue scale, number of bibs changed daily and drool quotient (P < 0.001). Mean quality of life scores dropped from 35 ± 4.8 at baseline to 29 ± 5.2) at week 8 (P < 0.001). Caregiver satisfaction was high at weeks 2, 8 and 16. Pain or swelling (19%), excessively thick saliva (9.5%), fever (9.5%) and chewing difficulties (4.8%) were transient and subsided within 2 weeks of the injection. Eighteen (87.5%) caregivers indicated they wanted repeat injections in the future. In conclusion, percutaneous intraglandular injection of BTX-A was safe and had a sustained effect for up to 16 weeks, with a concomitant improvement in their quality of life and caregiver satisfaction.

Original languageEnglish
Pages (from-to)141-145
Number of pages5
JournalJournal of Pediatric Neurology
Volume7
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Sialorrhea
Type A Botulinum Toxins
Cerebral Palsy
Caregivers
Quality of Life
Injections
Submandibular Gland
Mastication
Therapeutics
Salivary Glands
Visual Analog Scale
Saliva
Fever
Pain

Keywords

  • Botulinum toxin A
  • Cerebral palsy
  • Children
  • Sialorrhea

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

@article{b63057fe999f47b1b2def4c79422d1f1,
title = "Treatment of drooling in children with cerebral palsy using ultrasound guided intraglandular injections of botulinum toxin A",
abstract = "The aim of this study was to determine whether botulinum toxin A (BTX-A), injected into both parotid and submandibular salivary glands of children with cerebral palsy and sialorrhea, could decrease their drooling and improve their quality of life. Twenty-one children aged 4 to 12 years (mean age 8.4 years) received 60-80 units BTX-A (mean dose 3.6 U/kg) under sedation using ultrasound guidance. Response was assessed by several methods (drool frequency and severity score, drool quotient, number of bib changes per day and a visual analogue score) at baseline, 2, 8 and 16 weeks post-injection. A questionnaire related to quality of life and caregiver satisfaction was administered at baseline and week 8. Adverse events were recorded at each visit. Drool frequency and severity scores were significantly reduced at weeks 2, 8 and 16 compared to baseline (P < 0.001). Significant reductions were also seen for the visual analogue scale, number of bibs changed daily and drool quotient (P < 0.001). Mean quality of life scores dropped from 35 ± 4.8 at baseline to 29 ± 5.2) at week 8 (P < 0.001). Caregiver satisfaction was high at weeks 2, 8 and 16. Pain or swelling (19{\%}), excessively thick saliva (9.5{\%}), fever (9.5{\%}) and chewing difficulties (4.8{\%}) were transient and subsided within 2 weeks of the injection. Eighteen (87.5{\%}) caregivers indicated they wanted repeat injections in the future. In conclusion, percutaneous intraglandular injection of BTX-A was safe and had a sustained effect for up to 16 weeks, with a concomitant improvement in their quality of life and caregiver satisfaction.",
keywords = "Botulinum toxin A, Cerebral palsy, Children, Sialorrhea",
author = "Ong, {Lai Choo} and Wong, {Sau Wei} and {Abdul Hamid}, Hamzaini",
year = "2009",
doi = "10.3233/JPN-2009-0293",
language = "English",
volume = "7",
pages = "141--145",
journal = "Journal of Pediatric Neuroradiology",
issn = "1304-2580",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Treatment of drooling in children with cerebral palsy using ultrasound guided intraglandular injections of botulinum toxin A

AU - Ong, Lai Choo

AU - Wong, Sau Wei

AU - Abdul Hamid, Hamzaini

PY - 2009

Y1 - 2009

N2 - The aim of this study was to determine whether botulinum toxin A (BTX-A), injected into both parotid and submandibular salivary glands of children with cerebral palsy and sialorrhea, could decrease their drooling and improve their quality of life. Twenty-one children aged 4 to 12 years (mean age 8.4 years) received 60-80 units BTX-A (mean dose 3.6 U/kg) under sedation using ultrasound guidance. Response was assessed by several methods (drool frequency and severity score, drool quotient, number of bib changes per day and a visual analogue score) at baseline, 2, 8 and 16 weeks post-injection. A questionnaire related to quality of life and caregiver satisfaction was administered at baseline and week 8. Adverse events were recorded at each visit. Drool frequency and severity scores were significantly reduced at weeks 2, 8 and 16 compared to baseline (P < 0.001). Significant reductions were also seen for the visual analogue scale, number of bibs changed daily and drool quotient (P < 0.001). Mean quality of life scores dropped from 35 ± 4.8 at baseline to 29 ± 5.2) at week 8 (P < 0.001). Caregiver satisfaction was high at weeks 2, 8 and 16. Pain or swelling (19%), excessively thick saliva (9.5%), fever (9.5%) and chewing difficulties (4.8%) were transient and subsided within 2 weeks of the injection. Eighteen (87.5%) caregivers indicated they wanted repeat injections in the future. In conclusion, percutaneous intraglandular injection of BTX-A was safe and had a sustained effect for up to 16 weeks, with a concomitant improvement in their quality of life and caregiver satisfaction.

AB - The aim of this study was to determine whether botulinum toxin A (BTX-A), injected into both parotid and submandibular salivary glands of children with cerebral palsy and sialorrhea, could decrease their drooling and improve their quality of life. Twenty-one children aged 4 to 12 years (mean age 8.4 years) received 60-80 units BTX-A (mean dose 3.6 U/kg) under sedation using ultrasound guidance. Response was assessed by several methods (drool frequency and severity score, drool quotient, number of bib changes per day and a visual analogue score) at baseline, 2, 8 and 16 weeks post-injection. A questionnaire related to quality of life and caregiver satisfaction was administered at baseline and week 8. Adverse events were recorded at each visit. Drool frequency and severity scores were significantly reduced at weeks 2, 8 and 16 compared to baseline (P < 0.001). Significant reductions were also seen for the visual analogue scale, number of bibs changed daily and drool quotient (P < 0.001). Mean quality of life scores dropped from 35 ± 4.8 at baseline to 29 ± 5.2) at week 8 (P < 0.001). Caregiver satisfaction was high at weeks 2, 8 and 16. Pain or swelling (19%), excessively thick saliva (9.5%), fever (9.5%) and chewing difficulties (4.8%) were transient and subsided within 2 weeks of the injection. Eighteen (87.5%) caregivers indicated they wanted repeat injections in the future. In conclusion, percutaneous intraglandular injection of BTX-A was safe and had a sustained effect for up to 16 weeks, with a concomitant improvement in their quality of life and caregiver satisfaction.

KW - Botulinum toxin A

KW - Cerebral palsy

KW - Children

KW - Sialorrhea

UR - http://www.scopus.com/inward/record.url?scp=65449148285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449148285&partnerID=8YFLogxK

U2 - 10.3233/JPN-2009-0293

DO - 10.3233/JPN-2009-0293

M3 - Article

AN - SCOPUS:65449148285

VL - 7

SP - 141

EP - 145

JO - Journal of Pediatric Neuroradiology

JF - Journal of Pediatric Neuroradiology

SN - 1304-2580

IS - 2

ER -